title: Radiotherapy and concurrent low-dose paclitaxel in locally advanced head and neck cancer.
abstract: In our prospective study we examined the use of low-dose paclitaxel concurrently with radiation for patients with locally advanced head and neck cancer, who were not eligible for concurrent chemoradiation due to their poor general condition. Twenty-six patients were treated with external beam radiotherapy and received concomitantly 2 mg/m(2) paclitaxel three times a week. Beside an acceptable efficacy (RR: 65%, 2-year overall survival 46%) the treatment was well tolerated and resulted in a favorable toxicity profile. This regimen is resource effective and allowed successive therapy if it was necessary and therefore may serve as an alternative for patients in poor condition with locally advanced head and neck cancer.
authors.affiliation: Department of Radiotherapy, National Institute of Oncology, Budapest, Hungary.
authors.forename: József
authors.initials: J
authors.lastname: Lövey
authors.forename: Krisztina
authors.initials: K
authors.lastname: Koronczay
authors.forename: Eva
authors.initials: E
authors.lastname: Remenár
authors.forename: Orsolya
authors.initials: O
authors.lastname: Csuka
authors.forename: György
authors.initials: G
authors.lastname: Németh
mesh_terms: D000328:Adult; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage*; D011446:Prospective Studies; D011832:Radiation Injuries; D011879:Radiotherapy Dosage; D015996:Survival Rate
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel